MARKET

ELVN

ELVN

Enliven Therapeutics Inc
NASDAQ
51.20
-0.35
-0.68%
Pre Market: 51.00 -0.2 -0.39% 04:00 11/11 EST
OPEN
50.08
PREV CLOSE
51.55
HIGH
51.81
LOW
49.74
VOLUME
15
TURNOVER
0
52 WEEK HIGH
62.32
52 WEEK LOW
14.79
MARKET CAP
3.77B
P/E (TTM)
-30.1407
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ELVN last week (1102-1106)?
Weekly Report · 2d ago
Enliven Therapeutics Stock Losses Widen As Phase 3 Trial Plan Gets FDA Alignment
Simply Wall St · 3d ago
Enliven Therapeutics (ELVN) On FDA Trial Alignment And The Case For More Upside
Simply Wall St · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: SCYNEXIS (SCYX), Enliven Therapeutics (ELVN)
TipRanks · 4d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 4d ago
Enliven Therapeutics Price Target Maintained With a $78.00/Share by Guggenheim
Dow Jones · 4d ago
Guggenheim Reiterates Buy on Enliven Therapeutics, Maintains $78 Price Target
Benzinga · 4d ago
Enliven Therapeutics GAAP EPS of -$0.36
Seeking Alpha · 5d ago
More
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.

Webull offers Enliven Therapeutics Inc stock information, including NASDAQ: ELVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELVN stock methods without spending real money on the virtual paper trading platform.